Astellas strengthens gene therapy portfolio with Iveric Bio acquisition

CREDIT: GOOGLE

Astellas Pharma has acquired Iveric Bio, a US-based biotech firm, for $5.9 billion.

CREDIT: GOOGLE

Astellas strengthens gene therapy portfolio with Iveric Bio acquisition

The deal is expected to bolster Astellas' portfolio in ophthalmology and gene therapy.

CREDIT: GOOGLE

Iveric Bio's Zimura could become a blockbuster drug

Iveric Bio's lead drug candidate, Zimura, is a treatment for a degenerative eye disease known as geographic atrophy.

CREDIT: GOOGLE

Astellas expands presence in US market with Iveric Bio purchase

Zimura has shown promising results in clinical trials and could become a blockbuster drug with potential annual sales of over $1 billion.

CREDIT: GOOGLE

Astellas to acquire Iveric Bio to boost ophthalmology portfolio

The acquisition is part of Astellas' strategy to expand its presence in the US market.

CREDIT: GOOGLE

Iveric Bio to become Astellas' wholly-owned subsidiary

The transaction is expected to close by the end of 2021, subject to regulatory approval and other customary closing conditions.

CREDIT: GOOGLE

Astellas' largest-ever purchase of a biotech firm Iveric Bio

Iveric Bio will become a wholly-owned subsidiary of Astellas following the acquisition.

CREDIT: GOOGLE

Astellas financing Iveric Bio acquisition with cash and bank borrowings

The acquisition represents Astellas' largest-ever purchase of a biotech firm.

CREDIT: GOOGLE

Astellas to acquire Iveric Bio pending regulatory approval

Astellas will finance the acquisition using cash on hand and borrowings from banks.

CREDIT: GOOGLE

Astellas aims to grow through Iveric Bio acquisition

The acquisition is expected to be accretive to Astellas' earnings in the medium term.

CREDIT: GOOGLE

Iveric Bio's Zimura shows promising results in clinical trials